Abstract
Background: To evaluate the potential added benefit of opicapone (OPC), versus placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson's disease (PD) patients from the BIPARK-I trial who were recently diagnosed with motor fluctuations ('recent fluctuators'; defined as having an onset of motor fluctuations < /=1 year of study baseline).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call